FDA Approves Second Alzheimer’s Drug after Trial Shows it Can Slow Disease by 35%
The Federal Drug Administration gave the go-ahead to a second Alzheimer’s treatment Tuesday after a study suggested that it could slow the symptoms of the disease.
The drug, developed by Eli Lilly, is called donanemab and will be sold under the name “Kisunla” when it hits the market. The pharmaceutical giant has not set a release date.
Eli Lilly, which makes the anti-obesity drug Mounjaro, saw its shares rise slightly on the FDA approval.